Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation-Reference-Cited by-同舟云学术

Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation

Published:2020-06 Issue:6 Volume:15 Page:1015-1026
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Shi Yuankai,Zhang Shucai,Hu Xingsheng,Feng Jifeng,Ma Zhiyong,Zhou Jianying,Yang Nong,Wu Lin,Liao Wangjun,Zhong Dafang,Han Xiaohong,Wang Ziping,Zhang Xiaodong,Qin Shukui,Ying Kejing,Feng Jian,Fang Jian,Liu Li,Jiang Yong

Funder

Shanghai Allist Pharmaceuticals Co., Ltd.

China National Major Project for New Drug Innovation

Chinese Academy of Medical Sciences

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update;Masters;J Clin Oncol,2015

3. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016;Tan;J Thorac Oncol,2016

4. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

5. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial;Shi;Lancet Oncol,2013

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib;Toxicology;2024-09

2. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer;The Lancet Regional Health - Western Pacific;2024-07

3. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation;Frontiers in Oncology;2024-06-11

4. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy;Molecules;2024-03-23

5. Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report;Anti-Cancer Drugs;2024-03-15